{"doi":"10.1002/jha2.70041","title":"Nivolumab Induces Durable Remission in Relapsed/Refractory ALK‐Negative ALCL After Allogeneic Blood Stem Cell Transplantation—A Case Report and Literature Review","abstract":"<jats:title>ABSTRACT</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Relapsed or refractory anaplastic large cell lymphoma (r/r‐ALCL) remains an important therapeutic challenge, especially after allogeneic stem cell transplantation (alloHSCT). Due to encouraging results in other lymphoid diseases, PD‐1 blockade was investigated in T‐cell lymphoma in a small number of patients, but short duration of remission and significant adverse events were observed.</jats:p></jats:sec><jats:sec><jats:title>Case Report</jats:title><jats:p>Here, we report successful and durable remission induction for more than 2 years with nivolumab for r/r‐ALCL even without any evidence of PD‐L1 expression.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>This report and literature review emphasizes the importance of the graft‐versus‐lymphoma effect and its potential pharmacological stimulators in the field of lymphoma treatment.</jats:p></jats:sec>","journal":"eJHaem","year":2025,"id":611983,"datarank":0.10397207708399181,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"self_citation_contribution":0.10397207708399181,"citation_network_contribution":0.0,"self_endowment_contribution":0.10397207708399181,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":1,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1016770,"name":"Kathrin Nachtkamp","orcid":"0000-0001-5893-2298","position":1,"is_corresponding":false},{"id":1575457,"name":"Paul Jäger","orcid":"0000-0001-9250-2064","position":2,"is_corresponding":false},{"id":1575458,"name":"Paula Kessler","orcid":null,"position":3,"is_corresponding":false},{"id":1575459,"name":"Emil Novruzov","orcid":null,"position":4,"is_corresponding":false},{"id":235078,"name":"Frederik L. Giesel","orcid":"0000-0002-9669-5593","position":5,"is_corresponding":false},{"id":1575460,"name":"Helena Peters","orcid":null,"position":6,"is_corresponding":false},{"id":531893,"name":"Maximilian Seidl","orcid":"0000-0002-5559-4980","position":7,"is_corresponding":false},{"id":1575461,"name":"Mark Uhlenbruch","orcid":null,"position":8,"is_corresponding":false},{"id":813378,"name":"Sascha Dietrich","orcid":"0000-0002-0648-1832","position":9,"is_corresponding":false},{"id":1016772,"name":"Guido Kobbe","orcid":"0000-0002-9745-8813","position":10,"is_corresponding":false},{"id":1575456,"name":"Ben‐Niklas Baermann","orcid":"0009-0000-1699-9478","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Nivolumab Induces Durable Remission in Relapsed/Refractory ALK‐Negative ALCL After Allogeneic Blood Stem Cell Transplantation—A Case Report and Literature Review","abstract":"<jats:title>ABSTRACT</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Relapsed or refractory anaplastic large cell lymphoma (r/r‐ALCL) remains an important therapeutic challenge, especially after allogeneic stem cell transplantation (alloHSCT). Due to encouraging results in other lymphoid diseases, PD‐1 blockade was investigated in T‐cell lymphoma in a small number of patients, but short duration of remission and significant adverse events were observed.</jats:p></jats:sec><jats:sec><jats:title>Case Report</jats:title><jats:p>Here, we report successful and durable remission induction for more than 2 years with nivolumab for r/r‐ALCL even without any evidence of PD‐L1 expression.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>This report and literature review emphasizes the importance of the graft‐versus‐lymphoma effect and its potential pharmacological stimulators in the field of lymphoma treatment.</jats:p></jats:sec>","is_dataset_classified":null,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"40469417","pmcid":"PMC12136181","openalex_id":"https://openalex.org/W4411018504","authors":[],"funders":[],"total_grants":0,"fwci":0.7875,"citation_percentile":0.70557057,"influential_citations":0,"citation_trend":[{"year":2026,"count":1}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jha2.70041","host_type":"journal"},{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jha2.70041","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.70041","host_type":"publisher"},{"url":"https://doi.org/10.1002/jha2.70041","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/40469417","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/12136181","host_type":"repository"},{"url":"https://doaj.org/article/a4241549f8b44c068d52626f7120324d","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC12136181","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC12136181?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Lymphoma Diagnosis and Treatment","CAR-T cell therapy research","Cutaneous lymphoproliferative disorders research"],"mesh_terms":[],"keywords":["Nivolumab","Medicine","Refractory (planetary science)","Complete remission","Lymphoma","Transplantation","Anaplastic large-cell lymphoma","Adverse effect","Stem cell","Oncology","Internal medicine","Gastroenterology","Immunotherapy","Chemotherapy","Cancer","Biology","GVHD","Stem cell transplantation","Case Report","T‐cell Lymphoma"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-02T00:33:32.895817Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}